CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount of $6.20 million for the 12-month period ending 2021-12-25, per its 10-K filed 2022-02-16.
Discontinued › Notes › Investments › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount · last filed 2022-02-16
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2021 was $6.20M.
| Period end | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2021-12-25 | $6.20M 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |